The DAPLO DAPLOGIN trademark dispute between Dr. Reddy’s Laboratories Limited and Razenta Pharmaceuticals Private Limited is an important development in pharmaceutical trademark law in India. The Delhi High Court found the DAPLOGIN trademark deceptively similar to Dr. Reddy’s earlier DAPLO trademark and directed the Registrar of Trademarks to cancel the DAPLOGIN registration.
The case is particularly significant because the rival pharmaceutical products contained the same active pharmaceutical ingredient (API) and were used for the treatment of Type-2 Diabetes Mellitus.
Quick Summary
The Delhi High Court ruled in favour of Dr. Reddy’s Laboratories in the DAPLO–DAPLOGIN trademark dispute. The Court found DAPLOGIN deceptively similar to the earlier DAPLO mark and directed cancellation of the DAPLOGIN registration. The decision highlights the importance of distinctive pharmaceutical trademarks and careful assessment of confusion in medicine brand names.
Overview of the DAPLO–DAPLOGIN Trademark Dispute
| Particular | Details |
|---|---|
| Case | DAPLO vs DAPLOGIN trademark dispute |
| Plaintiff/earlier mark owner | Dr. Reddy’s Laboratories Limited |
| Earlier trademark | DAPLO |
| Disputed trademark | DAPLOGIN |
| Other party | Razenta Pharmaceuticals Private Limited |
| Court | Delhi High Court |
| Products | Pharmaceutical products |
| API | Same API, as noted by the Court |
| Therapeutic use | Type-2 Diabetes Mellitus |
| Outcome | DAPLOGIN registration directed to be cancelled |
What Was the Dispute About?
The dispute arose over the pharmaceutical trademarks DAPLO and DAPLOGIN.
Dr. Reddy’s Laboratories had an earlier registered trademark for DAPLO. Razenta Pharmaceuticals subsequently used the mark DAPLOGIN for a competing pharmaceutical product.
Dr. Reddy’s challenged the registration and use of DAPLOGIN, arguing that the mark was deceptively similar to its existing DAPLO trademark.
The Delhi High Court considered the similarity between the marks along with the nature and therapeutic use of the competing pharmaceutical products.
What Did the Delhi High Court Decide?
The Delhi High Court held that DAPLOGIN was deceptively similar to DAPLO.
The Court directed the Registrar of Trademarks to rectify the register and remove the DAPLOGIN trademark. The registration was directed to be cancelled within six weeks.
The judgment was delivered by Justice Jyoti Singh.
Why Was DAPLOGIN Considered Deceptively Similar to DAPLO?
The Court considered several relevant factors while examining the similarity between the two marks.
1. Similarity Between the Brand Names
The marks DAPLO and DAPLOGIN share a significant phonetic and structural similarity.
In pharmaceutical trademarks, similarity in pronunciation can be particularly important because medicine names may be communicated verbally between doctors, pharmacists, patients and other healthcare professionals.
2. Same Active Pharmaceutical Ingredient
The rival products contained the same active pharmaceutical ingredient (API), according to the judgment.
This increased the relevance of the similarity between the two brand names.
3. Same Therapeutic Purpose
Both products were used for the treatment of Type-2 Diabetes Mellitus.
Therefore, the products operated in the same therapeutic field rather than being unrelated pharmaceutical goods.
4. Reputation and Goodwill of DAPLO
The Court also considered the goodwill, reputation, investments and revenues associated with the DAPLO mark.
The Court found that DAPLO satisfied the relevant parameters for recognition as a well-known trademark under the applicable provisions of the Trade Marks Act, 1999.
Does Prescription Status Prevent Trademark Confusion?
No.
One of the important aspects of the judgment is that the fact that both products were prescription medicines was not considered sufficient to eliminate the possibility of confusion.
The Court considered that similarity in pharmaceutical brand names, including phonetic similarity, can still create confusion despite medicines being sold on prescription.
This is particularly important in the pharmaceutical sector because confusion between medicine names can potentially have serious consequences.
Key Legal Provisions Considered
The judgment considered provisions of the Trade Marks Act, 1999, including:
| Provision | Broad relevance |
| Section 9(1)(a) | Absolute grounds relating to distinctive character of trademarks |
| Section 9(2)(a) | Registration where use may cause confusion or deceive |
| Section 11(1)(b) | Relative grounds involving similarity with earlier trademarks |
The Court found that the registration of DAPLOGIN fell foul of the relevant trademark provisions.
Why Is This Judgment Important for the Pharmaceutical Industry?
The DAPLO DAPLOGIN trademark dispute highlights the need for pharmaceutical companies to conduct detailed trademark due diligence before adopting or registering a new medicine brand.
A brand name should not be assessed only on the basis of its spelling. Companies should also consider:
- Phonetic similarity
- Visual similarity
- Existing pharmaceutical trademarks
- Therapeutic indication
- API or composition
- Target consumers
- Marketing and distribution channels
- Likelihood of confusion
Impact on Pharmaceutical Trademark Protection
The ruling reinforces the importance of protecting established pharmaceutical trademarks and their associated goodwill.
For companies developing new pharmaceutical brands, the case demonstrates why trademark clearance should be conducted before launching a product or applying for registration.
Key Lessons for Pharma Companies
- Conduct comprehensive trademark searches before selecting a brand name.
- Check phonetic similarity, not just spelling.
- Review existing trademarks in the same therapeutic segment.
- Assess the API and therapeutic indication of competing products.
- Evaluate the likelihood of confusion among doctors, pharmacists and consumers.
- Consider the reputation and goodwill associated with existing pharmaceutical marks.
- Obtain appropriate legal and trademark advice before commercial adoption.
What Does the Judgment Mean for Pharmacy Students?
For B.Pharm, D.Pharm, M.Pharm and pharmacy students, this case is useful for understanding how intellectual property law applies to pharmaceutical products.
The case demonstrates that pharmaceutical trademarks are not assessed only by looking at whether two names are exactly the same. Similarity, pronunciation, product characteristics and the likelihood of confusion can also become important.
This topic can be useful for students preparing for subjects and examinations involving Pharmaceutical Jurisprudence, Intellectual Property Rights and Pharmacy Law.
Important Takeaways
| Key Point | What It Means |
| DAPLO | Earlier registered trademark of Dr. Reddy’s Laboratories |
| DAPLOGIN | Trademark used by Razenta Pharmaceuticals |
| Similarity | Court found DAPLOGIN deceptively similar to DAPLO |
| API | Rival products contained the same API |
| Therapeutic use | Products were used for Type-2 Diabetes Mellitus |
| Prescription medicines | Prescription status did not automatically eliminate confusion |
| Court’s direction | DAPLOGIN registration to be removed from the register |
| Industry lesson | Pharma companies should conduct careful trademark clearance |
What Should Pharmaceutical Companies Do Before Launching a Brand?
Before adopting a new pharmaceutical brand name, companies should undertake a structured trademark review.
Recommended Trademark Checks
Step 1: Search existing registered and pending trademarks.
Step 2: Check visually similar names.
Step 3: Check phonetic and pronunciation similarities.
Step 4: Examine pharmaceutical products using similar names.
Step 5: Compare therapeutic indications and APIs where relevant.
Step 6: Assess the likelihood of confusion.
Step 7: Obtain professional trademark advice before finalising the brand.
FAQs on the DAPLO–DAPLOGIN Trademark Dispute
1. What is the DAPLO DAPLOGIN trademark dispute?
The dispute involved Dr. Reddy’s Laboratories’ earlier DAPLO trademark and Razenta Pharmaceuticals’ DAPLOGIN trademark. The Delhi High Court found DAPLOGIN deceptively similar to DAPLO.
2. What did the Delhi High Court decide?
The Court ruled in favour of Dr. Reddy’s Laboratories and directed the Registrar of Trademarks to remove the DAPLOGIN trademark from the register.
3. Why was DAPLOGIN considered similar to DAPLO?
The Court considered the similarity between the marks along with the fact that the rival pharmaceutical products contained the same API and were used for the same therapeutic purpose.
4. What condition were the rival medicines used to treat?
According to the judgment, the competing products were used for the treatment of Type-2 Diabetes Mellitus.
5. Does prescription-only status prevent trademark confusion?
No. The Court observed that the fact that the medicines were prescription products was not enough to eliminate the possibility of confusion.
6. Which trademark did Dr. Reddy’s Laboratories own?
Dr. Reddy’s Laboratories had an earlier registered trademark for DAPLO.
7. What happened to the DAPLOGIN trademark?
The Delhi High Court directed the Registrar of Trademarks to rectify the register and cancel/remove the DAPLOGIN trademark within the specified period.
8. Why is this case important for pharmaceutical companies?
The case highlights the importance of selecting distinctive medicine brand names and conducting detailed trademark searches to reduce the risk of confusion and trademark disputes.
Conclusion
The DAPLO DAPLOGIN trademark dispute is an important development in Indian pharmaceutical trademark law. The Delhi High Court found DAPLOGIN deceptively similar to DAPLO and directed the cancellation of the DAPLOGIN trademark registration.
The judgment also highlights that prescription status does not automatically eliminate the possibility of confusion between pharmaceutical brand names.
For pharmaceutical companies, the case reinforces the importance of comprehensive trademark searches, phonetic checks and careful assessment of competing products before adopting a new brand name.
For pharmacy students and pharma professionals, the case provides a useful practical example of how trademark protection and pharmaceutical brand-name confusion are considered under Indian trademark law.
Recommended Products
